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Summary Objective: To demonstrate that 5 days of treatment with a new
fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with
levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB).
Design: Randomized, double-blind, double dummy, multicentre, parallel group study
Setting: Sixty different medical centers in US, UK and Germany.
Material and methods: A total of 360 adults (440 years of age) with AECB were
randomly assigned to receive gemifloxacin 320mg once daily for 5 days or
levofloxacin 500mg once daily for 7 days. The primary efficacy parameter was a
clinical response at follow-up (Days 14–21).
Results: In total, 335/360 patients completed the study (93.1%). Seven patients
receiving gemifloxacin withdrew from the study compared to 18 patients receiving
levofloxacin; this difference was statistically significant (Fisher’s exact test:
p¼ 0.02). In the intent-to-treat (ITT) population, the clinical success rate at
follow-up (Days 14–21) was 85.2% (155/182) with gemifloxacin and 78.1% (139/178)
with levofloxacin. Clinical success rate in the per-protocol (PP) population was 88.2%
(134/152) with gemifloxacin and 85.1% (126/148) with levofloxacin. At long-term
follow-up (Days 28–35), the clinical success rates in the PP population were 83.7%
(123/147) with gemifloxacin and 78.4% (109/139) with levofloxacin. The difference
in success rates was 5.26% (95% CI: 3.83, 14.34).
Conclusion: The clinical efficacy of gemifloxacin 320mg once daily for 5 days in
AECB was at least as good as levofloxacin 500mg once daily for 7 days. Fewer
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withdrawals and superior clinical efficacy at long-term follow-up were also seen with
gemifloxacin.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic bronchitis is defined as chronic bronchial
mucosal inflammation, characterized by cough and
excessive sputum production for more than two
consecutive years and for most days in a consecu-
tive 3-month period. The disease is caused by
prolonged exposure to irritants, the most promi-
nent of which is cigarette smoke, although atmo-
spheric pollution and recurrent episodes of
infection may also play a role. Patients with chronic
bronchitis frequently experience episodes of acute
disease (exacerbations) superimposed on the
chronic process. These exacerbations are charac-
terized by increased cough, increased sputum
volume and purulence, and respiratory distress.1
A study of chronic obstructive pulmonary disease in
the USA, recently reported a large increase in the
annual death rate among women, rising from 20/
100,000 in 1980, to 57/100,000 in 2000 whereas,
although the death rate among men was higher, the
increase was more modest rising from 73 to 83 per
100,000 over the same period.2 It has been
calculated that the total treatment costs for
acute exacerbations of chronic bronchitis (AECB)
are $1.2 billion for patients aged 65 years and over,
and $419 million for patients aged o65 years; and
as the majority of the costs are related to
hospitalization, it was concluded that any new
treatment that allows more patients to be treated
in the community is likely to generate significant
cost savings.3
Pathogens commonly associated with acute bac-
terial exacerbation of chronic bronchitis are Hae-
mophilus influenzae (40%), Streptococcus
pneumoniae (15–20%) and Moraxella catarrhalis
(15%). The increasing evidence of antibacterial
resistance in these pathogens has raised concern
about the efficacy of many of the standard
therapies. A recent report on 1998–2000 data from
the Alexander Project found b-lactamase produc-
tion in 29.6% of H. influenzae from the US, showing
a 6.3% increase from the 1997 data.4 Penicillin-
resistant S. pneumoniae has also been identified
worldwide with a prevalence of penicillin resis-
tance varying from very low in Northern Europe to
approximately 40% in France, Spain, and the USA,
and upto 80% in Hong Kong and South Korea.
Macrolide resistant S. pneumoniae has recently
spread worldwide resulting in, for many countries,
a higher prevalence of macrolide resistant
S. pneumoniae than penicillin-resistant S. pneumo-
niae. Strains of S. pneumoniae resistant to both
penicillin and macrolides are common, posing
treatment problems with these classes of antibio-
tics.5 Multidrug-resistant S. pneumoniae (MDRSP)
are strains of pneumococci which are resistant to
three or more classes of antibiotic, currently 26%
of all S. pneumoniae are resistant to at least 3
different classes of antibacterial agents.4 Fluoro-
quinolone antibacterial agents have been available
for over 15 years however, with increasing resis-
tance to beta-lactams and macrolides, the fluor-
oquinolones have started to be widely used to treat
respiratory tract infections (RTIs) including AECB.
The more recent fluoroquinolones possess in-
creased activity against S. pneumoniae, as well as
good activity against H. influenzae and M. catar-
rhalis, making them more suitable for broad
spectrum cover of RTIs. Indeed, fluoroquinolones
have been recommended as first-line therapy for
patients with AECB who are at higher risk of failure
on standard therapies.6,7
Gemifloxacin is a new broad-spectrum fluoroqui-
nolone with a favourable safety profile and con-
venient short duration dosing in AECB (once a day
for 5 days), which should contribute to high patient
compliance. Gemifloxacin has a high degree of
in vitro potency against S. pneumoniae and other
Gram-positive bacteria, including activity against
strains resistant to other quinolones. This improved
antimicrobial activity is due in part to the dual
mode of action of gemifloxacin against S. pneumo-
niae being active against both DNA gyrase and DNA
topoisomerase IV, both enzymes essential to DNA
replication.8 Recent studies of large numbers of
clinical isolates have shown gemifloxacin to possess
superior in vitro potency to comparator quinolone
agents. Gemifloxacin also has excellent in vitro
activity against beta-lactamase and non-beta-lac-
tamase producing strains of H. influenzae and
M. catarrhalis.4,9–11
The aim of this study was to demonstrate
that 5 days of treatment with gemifloxacin
was at least as effective and well tolerated
as 7 days of treatment with levofloxacin in
adult patients with AECB. Levofloxacin was se-
lected as the active comparator as it is the most
commonly prescribed fluoroquinolone agent for
RTIs.
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Methods
Patients
The study included patients aged440 years with a
history of chronic bronchitis defined as cough and
sputum production for more than 2 consecutive
years and for most days in a consecutive 3-month
period. Patients were also required to have an
acute exacerbation characterized by increased
purulent sputum together with increased cough
and increased dyspnoea. The severity of cough and
dyspnoea were rated by the physician as mild,
moderate or severe. In addition, the Hugh Jones
scale of assessment for dyspnoea was used. All
patients had to give written informed consent and
be willing to comply with the protocol require-
ments. Patients were excluded from the study if
they had cystic fibrosis, active tuberculosis,
bronchiectasis (with clinical signs and symptoms),
or active pulmonary malignancies. In addition,
patients were excluded if they had received
antibacterial therapy within the previous 7 days,
required parenteral antibacterial treatment, had
known or suspected hypersensitivity to quinolone
antibacterial agents, suffered tendinitis with pre-
vious fluoroquinolone therapy or had a complicating
infection or disease that would compromise treat-
ment evaluation of the study medication. Female
patients who were pregnant, lactating or planning
a pregnancy during the study were excluded, and
those who were of child-bearing potential or less
than 1 year postmenopausal and not using an
accepted method of contraception were also to
be excluded.
Study design
This was a randomized, double-blind, double
dummy, multicentre, parallel group study to assess
the clinical and antibacterial efficacy and safety of
oral gemifloxacin in comparison to oral levofloxacin
for the treatment of AECB. Patients who presented
at any time during an exacerbation that was
suitable for treatment with an oral antibacterial,
who fulfilled study entry criteria and had given
written, dated informed consent were randomized
in a double-blind fashion (1:1 ratio) to receive
either one of the coded medications (oral gemi-
floxacin 320mg once daily for 5 days and oral
levofloxacin-placebo once daily for 7 days or oral
levofloxacin 500mg once daily for 7 days and
oral gemifloxacin-placebo once daily for 5 days)
according to a pre-determined allocation schedule.
Each randomized patient was identified throughout
the study by a single randomization number. An
automated telephone system was used to allocate
treatment to patients. Patients were expected to
attend the clinic a maximum of five times over a
period of approximately 5 weeks to evaluate their
clinical and bacteriological response to treatment.
Clinical evaluation
The primary efficacy parameter was clinical re-
sponse at follow-up (Days 14–21). The secondary
efficacy parameters were as follows: clinical
response at end of therapy (Visit 3) and at long-
term follow-up (Visit 5), and bacteriological re-
sponse (success or failure) at follow-up (Visit 4),
end of therapy (Visit 3) and at long-term follow-up
(Visit 5). At end of therapy clinical success was
defined as sufficient improvement or resolution of
the signs and symptoms of AECB recorded at
screening such that no additional antibacterial
therapy was required for AECB; at follow-up the
definition was sustained improvement or resolution
of signs and symptoms of AECB for patients who
were clinical successes at the end of therapy visit,
such that no additional antibacterial therapy was
required for AECB and at the long-term follow-up
sustained improvement or resolution of signs and
symptoms of AECB for patients who were clinical
successes at the follow-up visit, such that no
additional antibacterial therapy was required for
AECB during long-term follow-up was the definition
of success. Not meeting the success criteria at any
visit, resulted in the patient being counted as a
failure unless there was some reason why the
investigator was unable to determine the clinical
outcome.
Bacteriological evaluation
Sputum samples were collected prior to the first
dose of study medication (Visit 1, Day 0) and where
possible at end of therapy (Visit 3, Days 9–11), at
follow-up (Visit 4, Days 14–21) and at long-term
follow-up (Visit 5, Days 28–35). If the patient
withdrew at the on-therapy visit (Days 2–4), a
sputum sample was collected at this visit. All
evaluable sputum samples were included in the
analyses. Any sputum cultures that did not meet
Gram staining criteria were deemed unevaluable.
Purulence was measured at the local laboratory by
microscopy and was defined as 425 white blood
cells per field ando10 squamous epithelial cells at
100magnification. Sputum Gram stain and cul-
ture were also conducted at the local laboratory.
All respiratory pathogens isolated were shipped to
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the central laboratory for confirmatory identifica-
tion and susceptibility testing. All susceptibility
testing was conducted according to National
Committee for Clinical Laboratory Standards
(NCCLS) guidelines.12
Safety
All patients who received at least one dose of study
medication were included in the safety population.
For each patient temperature, blood pressure,
pulse, and respiration rate were measured at each
of the scheduled visits. Blood samples were taken
prior to the first dose of study medication and at
the end of therapy for routine haematology and
clinical chemistry testing. An adverse event (AE)
was defined as any noxious, pathological or unin-
tended change in anatomical, physiological or
metabolic functions as indicated by physical signs,
symptoms and/or laboratory changes occurring in
any phase of the clinical study, whether considered
to be associated with the study medication or not.
This included any exacerbation of pre-existing
conditions or events, intercurrent illnesses, drug
interaction, or the significant worsening of the
disease under investigation that was not recorded
elsewhere in the case report form under specific
efficacy assessments.
Statistical methods
The primary efficacy analysis, and all secondary
variables relating to clinical and bacteriological
response, was based on an unstratified comparison
of proportions between the treatment groups. Two-
sided 95% confidence intervals (CIs) were used to
estimate the difference in the proportion of
successes between the treatment groups. A con-
clusion of non-inferior efficacy of gemifloxacin was
to be drawn for the primary efficacy endpoint if the
lower limit of the confidence interval (gemifloxacin
minus levofloxacin) was X13%. All CIs for differ-
ences in proportions were calculated using the
normal approximation to the binomial distribution.
The sample size was calculated from the assump-
tion of an underlying equivalent clinical response
rate of 85% at the follow-up visit. Three hundred
and eighteen evaluable patients (159 per treat-
ment arm) were required to give a power of 90% to
detect that the lower bound of the two-sided 95%
confidence interval for the difference in rates
(gemifloxacin group minus levofloxacin group) was
no less than 13%. This calculation was based on
the formula of Makuch and Simon.13 It was
anticipated that upto 20% of randomized patients
would be ineligible for the clinical PP population.
Therefore, approximately 400 patients were to be
recruited to provide 318 per protocol evaluable
patients.
Results
Study population
After consultation with the FDA, 39 patients from
one centre in the USA were excluded from the
analyses due to non-compliance with the protocol.
Therefore, a total of 361 patients from 61 centres
in Germany, UK and USA, were randomized to
receive study medication and 360 patients received
at least one dose; these 360 patients made up the
Safety Population and the Intent to Treat (ITT)
Population. The numbers of patients that com-
prised the various ITT and PP population by
treatment group and are shown in Table 1.
In total, 335/360 patients completed the study
(93.1%). There were seven patients withdrawn from
the group receiving gemifloxacin and 18 patients
withdrawn from the levofloxacin group; this differ-
ence was statistically significant (Fisher’s exact-
test: P¼ 0.02). The most frequently reported
reason for withdrawal in both treatment groups,
was an adverse event; 4/182 (2.2%) and 10/178
(5.6%) in the gemifloxacin and levofloxacin groups,
respectively. In the gemifloxacin treatment group,
the most frequent AEs leading to withdrawal were
diarrhoea and vomiting, which were reported in
1.1% (2/182) of patients whereas, in the levoflox-
acin treatment group, the AE most frequently
leading to withdrawal was nausea, also reported
in 1.1% (2/178) of patients. No other AE resulted in
the withdrawal of more than one patient in the
either treatment group. Of these AEs leading to
withdrawal, there were three gemifloxacin patients
and five levofloxacin patients, who had events that
were considered by the investigator to be of
suspected or probable relationship to the study
medication. In the gemifloxacin group these were
diarrhoea, nausea and vomiting, either alone or in
combination. In the levofloxacin group, these AEs
were more diverse: dizziness and hypesthesia;
pruritus; tendinitis; nausea and vomiting; and
diarrhoea.
There were no major differences between the
two treatment groups in the numbers of patients
that were excluded from the PP population at the
various timepoints. In the ITT population, the
treatment groups of gemifloxacin and levofloxacin
were well matched with respect to gender (male
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51.1% and 55.1%, female 48.9% and 44.9%, respec-
tively); age (mean 61.6 and 63.4 years, respec-
tively); race (96.2% and 96.6%, respectively were
white); height (mean 168 and 169 cm, respectively)
and weight (mean 76.4 and 79.2 kg, respectively)
and this pattern was also reflected in the PP
population.
At screening, the two treatment groups were
generally well matched with respect to disease
severity, as well as clinical and smoking history and
no major differences between the ITT and Clinical
PP populations were evident. The Ball and Wilson
classification of disease severity was used to
categorize the patient population: 97% (176)
patients in the gemifloxacin-treated group were
classified as Stage 2 (simple chronic bronchitis),
and 93% (166) of the levofloxacin-treated group
were Stage 2. The remaining patients in each group
were classified as Stage 3 (complicated chronic
bronchitis). A history of obstructive lung disease
was reported for 42% (77) of patients in the
gemifloxacin treatment group and for 46% (82) of
patients in the levofloxacin treatment group; 19%
(34) of the gemifloxacin treated group had a history
of asthma and 8% (15) specifically listed chronic
bronchitis in their history compared with 24% (26)
and 7% (12), respectively, for the levofloxacin-
treated patients. In the ITT population, more
patients in the levofloxacin treatment group
(53.9% (96/178)) had X30 smoking pack years
than in the gemifloxacin treatment group (45.1%
(8/182)) whereas, the gemifloxacin treatment
group had more patients (81 (44.5%) versus 67
(37.6%)) that were currently smoking at study entry
(Table 2). The mean duration of chronic bronchitis
was similar between the gemifloxacin and levo-
floxacin groups (11.9 and 12.7 years). The duration
of the current exacerbation was also very similar
between the groups at 8.5 and 8.2 days for the
gemifloxacin and levofloxacin groups. All the
patients reported an increase in the volume of
purulent sputum being expectorated, and 96.7%
(gemifloxacin) and 97.8% (levofloxacin) reported an
increase in the purulence of the sputum.
The percentage of patients with pathogens
recovered at screening was 24.2% in the gemiflox-
acin treatment group and 33.7% in the levofloxacin
treatment group. The MICs of gemifloxacin and
levofloxacin to all the major organisms isolated at
baseline are presented in Table 3. Gemifloxacin was
more potent than levofloxacin against all organ-
isms, and against S. pneumoniae was 32-fold more
active (MIC90 0.03 and 1mg/l for gemifloxacin and
levofloxacin, respectively).
Concomitant medication was being taken by
the vast majority of the study population (gemi-
floxacin: 95.6%, levofloxacin: 97.2%). The most
frequently reported therapy was salbutamol (gemi-
floxacin: 42.3%, levofloxacin: 41.0%). No major
differences were evident in the concomitant
medication usage between the two groups. Inhaled
and/or systemic steroids were received by 119/182
patients (65.4%) in gemifloxacin treatment group
and 116/178 patients (65.2%) in the levofloxacin
treatment group as a concomitant medication for
management of their chronic bronchitis or asthma.
A high proportion of patients in both groups were
compliant with the study medication (96.2% in the
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Table 1 Patient accounting and study populations.
Population Treatment Group
Gemifloxacin 320mg od,
N¼ 182
Levofloxacin 500mg od,
N¼ 179
Randomized 182 179
Received study medication (Safety & ITT) 182 178
Completed study 175 160
Number of patients withdrawn 7 18
Clinical PP on-therapy 170 164
Clinical PP end of therapy 160 155
Clinical PP follow-up 152 148
Clinical PP long-term follow-up 147 139
Bacteriology ITT 44 60
Bacteriology PP on-therapy 41 56
Bacteriology PP end of therapy 40 52
Bacteriology PP follow-up 37 49
Bacteriology PP long-term-follow-up 36 44
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Table 2 Demographics of study population and baseline AECB history.
Treatment group
Characteristic Gemifloxacin 320mg od,
N¼ 182
Levofloxacin 500mg od,
N¼ 178
Gender: n(%)
Male 93 (51.1) 98 (55.1)
Female 89 (48.9) 80 (44.9)
Age (year)
Mean (SD) 61.6 (11.6) 63.4 (10.5)
Range 34–90 39–89
Race: n(%)
White 175 (96.2) 172 (96.6)
Black 1 (0.5) 1 (0.6)
Oriental 3 (1.6) 1 (0.6)
Other 3 (1.6) 4 (2.2)
Weight (kg)
Mean (SD) 76.4 (17.6) 79.2 (20.9)
Range 38–152 44.5–204
Missing 0 1
Height (Cm)
Mean (SD) 168 (9.3) 169 (9.6)
Range 149–188 151–201
Missing 0 2
Duration of chronic bronchitis (year)
Mean (SD) 11.9 (10.5) 12.7 (12.3)
Range 2–56 2–61
Number of exacerbations treated with antibacterials in last year, n (%)
o4 142 (78.0) 137 (77.0)
X4 40 (22.0) 41 (23.0)
Used supplemental oxygen n (%) 18 (9.9) 19 (10.7)
Used systemic steriods in last year n (%) 50 (27.5) 52 (29.2)
Number of pack years patients has smoked, n (%)
0 38 (20.9) 39 (21.9)
40o30 62 (34.1) 43 (24.2)
X30 82 (45.1) 96 (53.9)
Smoking pack years, n (%)
Mean (SD) 34.0 (36.4) 35.4 (32.7)
Range 0–210 0–180
Currently smoke, n (%) 81 (44.5) 67 (37.6)
Missing 1 (0.5) 0
Duration of current exacerbation (days)
Mean (SD) 8.5 (12.1) 8.2 (15.5)
Range 1–90 1–180
Sputum, n (%)
Increased volume of purulent sputum 182 (100.0) 178 (100.0)
Increased sputum purulence 176 (96.7) 174 (97.8)
Cough, n (%)
Mild 16 (8.8) 14 (7.9)
Moderate 89 (48.9) 104 (58.4)
Severe 77 (42.3) 60 (33.7)
Dyspnoea, n (%)
Mild 49 (26.9) 37 (20.8)
Moderate 99 (54.4) 110 (61.8)
Severe 34 (18.7) 31 (17.4)
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gemifloxacin group and 93.3% in the levofloxacin
group).
Clinical efficacy
The primary efficacy outcome of clinical success
rate at follow-up (Days 14–21) in the Clinical PP
population was 88.2% (134/152) in the gemifloxacin
treatment group and 85.1% (126/148) in the
levofloxacin treatment group. In the ITT popula-
tion, the clinical success rate at follow-up was
85.2% (155/182) in the gemifloxacin group and
78.1% (139/178) in the levofloxacin group, support-
ing the Clinical PP result. The percentage of
patients whose outcome was ‘unable to determine’
was 0.5% in the gemifloxacin treatment group and
3.4% in the levofloxacin treatment group. In both
populations, the clinical efficacy of gemifloxacin
was shown to be at least as good as that of
levofloxacin as the lower limit of the 95% CI for the
treatment difference (gemifloxacin minus levoflox-
acin) was no less than 13% (Table 4).
The clinical success rate in the PP population at
end of therapy (Days 9–11) was 97.5% (156/160)
in the gemifloxacin treatment group and 93.5%
(145/155) in the levofloxacin treatment group. The
clinical success rate in the ITT population was
ARTICLE IN PRESS
Table 3 The activity of gemifloxacin and levo-
floxacin against the organisms isolated at baseline
in the two treatment groups.
Treatment group
Gemifloxacin Levofloxacin
H. influenzae n¼ 10 n¼ 13
MIC90 (mg/l) 0.004 0.03
Range (mg/l) 0.002–0.004 0.008–0.06
H. parainfluenzae n¼ 7 n¼ 7
MIC90 (mg/l) F
n F
Range (mg/l) 0.004–0.03 0.015–0.5
M. catarrhalis n¼ 6 n¼ 16
MIC90 (mg/l) F 0.06
Range (mg/l) 0.004–0.008 0.03–0.06
S. pneumoniae n¼ 6 n¼ 7
MIC90 (mg/l) F –
Range (mg/l) 0.015–0.03 0.5–1
S. aureus n¼ 4 n¼ 5
MIC90 (mg/l) F F
Range (mg/l) 0.008–0.03 0.06–48
P. aeruginosa n¼ 5 n¼ 9
MIC90 (mg/l) F F
Range (mg/l) 0.12–0.5 0.015–8
nMIC90 values are only shown for groups withX10 patient
isolates.
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94.0% in the gemifloxacin group and 88.8% in the
levofloxacin group (Table 4). At long-term follow-
up (Days 28–35), the clinical success rates in the
clinical PP population were 83.7% (123/147) and
78.4% (109/139) in the gemifloxacin and levoflox-
acin treatment groups, respectively. A total of 6/
147 patients (4.1%) in the gemifloxacin treatment
group and 8/139 patients (5.8%) in the levofloxacin
treatment group experienced a clinical recurrence
between the follow-up and long-term follow-up
visits. In the ITT population, clinical success rate at
long-term follow-up was 80.8% in the gemifloxacin
treatment group and 70.8% in the levofloxacin
treatment group. The 95% CI for the treatment
difference (1.18,18.78) shows statistical superiority
of gemifloxacin over levofloxacin for clinical effi-
cacy at long-term follow-up (28–35 days) in the ITT
population. This represents a lower response in the
levofloxacin group with a higher recurrence rate
over the study period and a more durable response
to 5 days of gemifloxacin therapy.
The robustness of the efficacy analysis was also
assessed by investigating severity of AECB at
baseline (Ball and Wilson Criteria) and smoking
pack years as categorical covariates. Neither of the
interactions between treatment and these covari-
ates were statistically significant (AECB severity
P¼ 0.53, smoking pack years: P¼ 0.49). For exam-
ple, clinical response at follow-up (Days 14–21)
by underlying severity of AECB, for the Clinical
PP follow-up population, showed that of those
patients with Stage 2 AECB (simple chronic bron-
chitis), 89.0% in the gemifloxacin treatment group
and 85.7% in the levofloxacin treatment group were
clinical successes. Similarly, the clinical response at
follow-up (Days 14–21), by smoking pack years, for
the Clinical PP follow-up population showed that of
those patients with an extensive smoking history
(i.e., at least 30 smoking pack years), 84.6% in the
gemifloxacin treatment group and 84.2% in the
levofloxacin treatment group were clinical suc-
cesses.
Bacteriological efficacy
Bacteriological efficacy was examined by per-
patient response (success/failure) and by the
per-pathogen response. The per-patient responses
of success at the key timepoints are shown in Fig. 1.
The success rate for levofloxacin was similar to that
of gemifloxacin at end of therapy (clinical PP:
87.5%, 90.4%; ITT: 81.8%, 86.7% for gemifloxacin
and levofloxacin, respectively) and at follow-up
(clinical PP: 78.4%, 85.7%; ITT: 75.0%, 80.0%), the
trend changed in favour of gemifloxacin at long-
term follow-up in both the clinical PP (77.8%,
70.5%) and the ITT (75.0%, 65.0%) populations,
suggesting a more sustained response.
In general, the per-pathogen responses were
good, eradication or presumed eradication of the
three major AECB pathogens at end of therapy
were H. influenzae 100% both groups, M. catar-
rhalis 100% both groups and S. pneumoniae 100%
in the gemifloxacin group and 83.3% (5/6) in
the levofloxacin group and at follow-up were
H. influenzae 100% in the gemifloxacin group and
90.9% (10/11) in the levofloxacin group, M. catar-
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Figure 1 Per-patient bacteriological response in the clinical PP and ITT populations at the key timepoints, ’
Gemifloxacin, clinical PP: end of therapy, n¼ 40; follow-up, n¼ 37; long-term follow-up, n¼ 36. ITT (all timepoints):
n¼ 44, & Levofloxacin, clinical PP: end of therapy, n¼ 52; follow-up, n¼ 49; long-term follow-up, n¼ 44. ITT (all
timepoints): n¼ 60.
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rhalis 83.3% (5/6) in the gemifloxacin group and
100% in the levofloxacin group, and S. pneumoniae
75% (3/4) in the gemifloxacin group and 80% (4/5)
in the levofloxacin group.
Safety
A total of 72/182 (39.6%) of patients in the
gemifloxacin treatment group and 60/178 (33.7%)
of patients in the levofloxacin treatment group
reported AEs. The four most frequent AEs reported
in the gemifloxacin treatment group were head-
ache (12/182; 6.6%), diarrhoea (10/182; 5.5%),
bronchitis (8/182; 4.4%) and nausea (8/182; 4.4%).
In the levofloxacin treatment group the four most
frequently reported AEs were diarrhoea (5/178;
2.8%), bronchitis (5/178; 2.8%), nausea (5/178;
2.8%) and rhinitis (5/178 (2.8%). The incidence of
erythematous rash and pustular rash in both the
treatment groups were low; 0.5% (1/182) gemi-
floxacin and 0.6% (1/178) levofloxacin. There were
no serious adverse events associated with skin-
associated AEs in either treatment group.
During the period on-therapy plus 30 days post-
therapy, serious AEs were reported by 2.7% (5/182)
of patients in the gemifloxacin treatment group and
6.7% (12/178) of patients in the levofloxacin
treatment group. Of these serious AEs none was
considered to be of probable or suspected relation-
ship to study medication. One levofloxacin-treated
patient died (myocardial infarction) however, the
death was not considered by the investigator to be
related to study medication.
Adverse events leading to withdrawal occurred in
4 patients (2.2%) in the gemifloxacin treatment
group and 10 patients (5.6%) in the levofloxacin
treatment group. In the gemifloxacin treatment
group, the most frequent AEs leading to withdrawal
were diarrhoea and vomiting in 1.1% (2/182) of
patients. No other AE resulted in the withdrawal of
patients in the gemifloxacin treatment group. In
the levofloxacin treatment group, the AE most
frequently leading to withdrawal was nausea in
1.1% (2/178) of patients.
The numbers of patients with treatment emer-
gent haematology or clinical chemistry values of
potential clinical concern were low in both treat-
ment groups. One patient in each treatment group
(0.6% gemifloxacin; 0.6% levofloxacin) had liver
function parameters of greater than 1.5–3 times
the upper limit of normal; neither elevation was
considered to be drug-related. One patient in each
treatment group had an elevation in QTc outside of
the normal range, but neither was associated with
any significant cardiac event.
Discussion
Antibacterial studies in patients with AECB can be
difficult to compare because the patients vary
considerably in the severity of the disease, co-
morbidities and the unknown proportion of patients
who do not have a bacterial exacerbation. Never-
theless, the clinical success rate in this study
(88.2%) compares very well with those of other
recent studies of 5 days of gemifloxacin in AECB:
86.8%,14 85.4%,15 91.5%.16
The results of this study demonstrated that the
clinical efficacy of gemifloxacin 320mg once daily
given orally for 5 days was at least as good as
levofloxacin 500mg once daily given orally for 7
days, for the treatment of AECB. The clinical
success rate at follow-up in clinically evaluable
patients was 88.2% in the gemifloxacin treatment
group and 85.1% in the levofloxacin treatment
group (treatment difference %: 3.02, 95% CI:
4.67, 10.72). Similar results were obtained for
the ITT population (85.2% versus 78.1%). Although
the study was not powered to demonstrate non-
inferiority for secondary endpoints, the clinical
success rates at the end of therapy in clinically
evaluable patients (97.5% for the gemifloxacin
treatment group and 93.5% for the levofloxacin
treatment group) demonstrated that the clinical
efficacy of gemifloxacin was at least as good as that
of levofloxacin (treatment difference %: 3.95, 95%
CI: 0.61, 8.51). Clinical success rates at long-term
follow-up were 83.7% for gemifloxacin and 78.4%
for levofloxacin treatment groups (treatment dif-
ference %: 5.26, 95% CI: 3.83,14.34). Clinical
success rates in the gemifloxacin group were
consistently higher than those of the levofloxacin-
treated patients and this reached statistical
significance at long-term follow-up in the ITT
population (6 weeks). This supports a statistically
significant durable response with gemifloxacin
which has also been observed in another
study.16
For bacteriologically evaluable patients, bacter-
iological success rates for the gemifloxacin and
levofloxacin treatment groups in Bacteriology PP
population were 87.5% and 90.4% at the end of
therapy, 78.4% and 85.7% at follow-up, and 77.8%
and 70.5% at long-term follow-up, respectively. Due
to the small number of bacteriologically evaluable
patients in these populations, no firm conclusions
can be drawn. Overall, bacterial eradication rates
for bacteriologically evaluable patients in the
gemifloxacin treatment group at follow-up were
100% for H. influenzae, 100% for H. parainfluenzae,
83.3% for M. catarrhalis and 75.0% for both
S. pneumoniae and S. aureus. These eradication
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rates were similar to those seen in the levofloxacin
treatment group.
There was a lower percentage of pathogens
recovered in sputum in this study relative to similar
studies in the literature. This may be a reflection of
the quality of the samples obtained. Indeed, the
disparity in the number of patients eligible for the
bacteriology ITT population in the gemifloxacin
treatment group (24.2% versus 33.7% in the levo-
floxacin group), is due primarily to the higher
number of patients in the gemifloxacin (99 pa-
tients; 54.4%) versus levofloxacin (89 patients;
50.0%) treatment groups having an unevaluable
sputum culture (i.e., culture not meeting Gram
staining criteria). In addition, there was generally a
higher proportion of pathogens recovered at
screening in the levofloxacin treatment group not
usually associated with AECB (e.g., P. aeruginosa).
Given that the study was not statistically powered
for secondary endpoints (i.e., the numbers of
bacteriological samples collected were small and
the resulting CIs were wide), firm conclusions
cannot be drawn with respect to the disparity
between the percentages of pretherapy organisms
obtain in the bacteriology ITT populations or with
respect to any correlation between clinical and
bacteriologic success. The low yield of pretherapy
organisms does not necessarily suggest that these
exacerbations were not bacterial, but rather there
may have been an issue with the samples them-
selves or with the central laboratory.
The in vitro activity of gemifloxacin against
S. pneumoniae isolates was consistent with MIC90
data collected in previous gemifloxacin AECB
studies. MIC results observed in this study confirm
the excellent in vitro activity of gemifloxacin,
which remains the most potent quinolone tested
against the primary respiratory pathogens, H.
influenzae, H. parainfluenzae, S. pneumoniae, M.
catarrhalis, and S. aureus, all having a
MIC90p0.06mg/ml. Gemifloxacin also demon-
strated lower MICs than levofloxacin against
Gram-negative pathogens including P. aeruginosa.
The in vitro potency of gemifloxacin to the primary
respiratory pathogens has been substantiated in
recent publications that compare gemifloxacin to
other beta-lactams and macrolides as well as other
quinolones.4,17–19.
A marker of drug tolerability is the withdrawal
rate due to adverse events thus from a safety
perspective, the tolerability of gemifloxacin was
good, as the withdrawal rate was markedly lower
with gemifloxacin (4 cases) than with levofloxacin
(10 cases). The four most frequent adverse events
reported in the gemifloxacin treatment group were
headache, diarrhoea, bronchitis and nausea,
whereas in the levofloxacin treatment group they
were diarrhoea, bronchitis, nausea and rhinitis. All
reported headaches in the gemifloxacin group were
of mild or moderate severityFonly one was
considered to be related to study medication. The
incidence of rash in both treatment groups was low;
0.5% (1/182) gemifloxacin and 0.6% (1/178) levo-
floxacin, in keeping with the generally low in-
cidence of this event in older patients and in short
treatment courses with gemifloxacin.20 There were
no serious adverse events associated with these
events in either treatment group.
Although all fluoroquinolones have proven effi-
cacy in AECB, in recent years surveillance studies
have regularly identified a growing number of
S. pneumoniae isolates that are resistant to
levofloxacin,21,22 and an increasing incidence of
reports of resistance related to clinical fail-
ures.23,24–26 In addition, levofloxacin-resistant H.
influenzae has emerged giving further cause for
concern.11 It has been suggested that the best way
to reduce the development of resistance is to
initially use the most active antimicrobial agents,27
and within each class, to use the most potent
agent. In this study, the clinical efficacy of
gemifloxacin 320mg once daily for 5 days was
shown to be at least as good as that of levofloxacin
500mg once daily for 7 days in the treatment of
patients with AECB. At long-term follow-up the
clinical efficacy of gemifloxacin was found to be
superior to that of levofloxacin. The low MICs of
gemifloxacin against all the major respiratory
pathogens, and particularly against S. pneumoniae,
showed gemifloxacin to be especially suitable for
the treatment of patients with respiratory tract
infections where effective cover of S. pneumoniae
and H. influenzae is essential. Gemifloxacin 320mg
once daily for 5 days is therefore an effective agent
in the treatment of patients with AECB. In
comparison with other antimicrobials, gemifloxacin
has the lowest MICs to all the major respiratory
pathogens, is given for 5 days, is efficacious,
particularly over a longer period, is well tolerated
and has few drug interactions or need for dosage
modification, each of which aids compliance. These
attributes may contribute to the lower propensity
for the emergence of resistance, an important
consideration in light of today’s increasing resis-
tance issues.
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